摘要
肝癌是我国高发、预后极差的恶性肿瘤之一,目前的治疗方法如手术、放疗、化疗等效果有限,开发新的治疗方法非常必要。免疫治疗是潜在的有效治疗手段之一。程序性死亡受体-1(programmed cell death receptor-1,PD-1)是一个重要的免疫卡控点,主要在活化的T淋巴细胞、B淋巴细胞和NK细胞上表达,具有免疫抑制作用。许多肿瘤细胞高表达程序性死亡配体-1(programmed cell death-ligand 1,PD-L1),PD-L1与T细胞等细胞表面的PD-1结合,发挥免疫负调控作用,使T淋巴细胞失能,形成肿瘤免疫逃逸。研究发现,对PD-1进行阻断可重建T淋巴细胞的免疫监视功能,延长肝癌等肿瘤患者总生存期。本文就PD-1为靶点的肝癌靶向治疗研究进展作一综述。如何通过联合治疗等手段最大限度地提高免疫卡控点抗体的应答率,同时降低免疫相关不良事件发生率,是亟需解决的关键问题。
Liver cancer is one of the malignant tumors with high incidence and extremely poor prognosis in China.Current treatments such as surgery,radiotherapy,and chemotherapy have been proved to be limited effects.It is very necessary to develop new therapeutic methods.Immunotherapy is one of the potentially effective treatments.Programmed cell death receptor-1(PD-1)is an important immune checkpoint,which is mainly expressed on activated T lymphocytes,B lymphocytes and NK cells,and has an immunosuppressive effect.Multiple tumors highly express programmed cell death-ligand 1(PD-L1),and PD-L1 binds to PD-1 on the surface of T cells and other cells,exerting negative immune regulation,leading to inactivation of T lymphocytes and thus tumor immune escape.A couple of studies have found that blockage of PD-1 can rebuild the immune surveillance function of T lymphocytes and prolong the overall survival of patients with liver cancer and other tumors.In this article,we have reviewed the advances of PD-1 targeted therapy for liver cancer.The key issue that needs to be solved is how to maximize the response rate of antibodies against immune checkpoints and meanwhile reduce the incidence of immune-related adverse events through combination therapy and other methods.
作者
吕玥茜
李茵佳
周素芳
LüYuexi;Li Yinjia;Zhou Sufang(Teaching and Research Section of Biochemistry,School of Basic Medical Sciences,Guangxi Medical University)
出处
《重庆医科大学学报》
CAS
CSCD
北大核心
2021年第5期630-634,共5页
Journal of Chongqing Medical University
基金
国家自然科学基金资助项目(编号:81872491)。
关键词
程序性死亡受体-1
抗体
免疫治疗
免疫卡控点
肝癌
programmed cell death receptor-1
antibody
immunotherapy
immune checkpoints
liver cancer
